肺内高利福平和异烟肼浓度与肺结核患者痰菌快速清除相关
在马拉维接受一线治疗的成年肺结核患者中,采用线性混合效应模型估算痰菌消除率,并构建群体药代动力学模型分析血浆与肺内药物暴露与痰菌清除的关系。结果显示上皮衬液中的利福平或异烟肼峰浓度或暴露量越高,痰菌消除越快、痰转阴时间越短;血浆或肺泡细胞药物暴露与痰菌清除无关。
要点
- 上皮衬液中利福平或异烟肼峰浓度或暴露量较高与痰菌消除更快、痰转阴时间更短相关。
- 血浆或肺泡细胞中的药物暴露与痰菌清除无关。
- 基线胸片病变更广泛与痰菌消除更慢相关。
核心结论
- 上皮衬液中利福平或异烟肼暴露量较高与痰菌清除更快相关。
- 较高剂量的利福平和异烟肼可能实现持续高肺内药物暴露、快速痰菌清除、缩短疗程和改善治疗结局。
研究设计与样本
- 在马拉维接受一线治疗的成年肺结核患者中开展药代动力学-药效学分析。
- 共纳入157例微生物学确诊肺结核患者,其中58%合并人类免疫缺陷病毒(HIV)感染。
- 采用线性混合效应模型估算痰菌消除率,并使用血浆和肺内药物水平构建群体药代动力学模型。
主要发现
- 血浆或肺泡细胞中的药物暴露与痰菌清除无关。
- 上皮衬液中利福平或异烟肼峰浓度或暴露量较高与痰菌消除更快、痰转阴时间更短相关。
- 基线胸片病变更广泛与痰菌消除更慢相关。
- 133例患者捕获临床结局,其中15例(11%)记录到不良结局(复发结核、治疗失败或死亡)。
- 未发现痰菌消除率与晚期临床结局之间的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intrapulmonary pharmacokinetics may better explain response to tuberculosis (TB) treatment than plasma pharmacokinetics. We explored these relationships by modeling bacillary clearance in sputum in adult patients on first-line treatment in Malawi. METHODS: Bacillary elimination rates (BER) were estimated using linear mixed-effects modelling of serial time-to-positivity in mycobacterial growth indicator tubes for sputum collected during the intensive phase of treatment (weeks 0-8) for microbiologically confirmed TB. Population pharmacokinetic models used plasma and intrapulmonary drug levels at 8 and 16 weeks. Pharmacokinetic-pharmacodynamic relationships were investigated using individual-level measures of drug exposure (area-under-the-concentration-time-curve [AUC] and Cmax) for rifampicin, isoniazid, pyrazinamide, and ethambutol, in plasma, epithelial lining fluid, and alveolar cells as covariates in the bacillary elimination models. RESULTS: Among 157 participants (58% human immunodeficiency virus [HIV] coinfected), drug exposure in plasma or alveolar cells was not associated with sputum bacillary clearance. Higher peak concentrations (Cmax) or exposure (AUC) to rifampicin or isoniazid in epithelial lining fluid was associated with more rapid bacillary elimination and shorter time to sputum negativity. More extensive disease on baseline chest radiograph was associated with slower bacillary elimination. Clinical outcome was captured in 133 participants, with 15 (11%) unfavorable outcomes recorded (recurrent TB, failed treatment, or death). No relationship between BER and late clinical outcome was identified. CONCLUSIONS: Greater intrapulmonary drug exposure to rifampicin or isoniazid in the epithelial lining fluid was associated with more rapid bacillary clearance. Higher doses of rifampicin and isoniazid may result in sustained high intrapulmonary drug exposure, rapid bacillary clearance, shorter treatment duration and better treatment outcomes.
引用
- McCallum AD, Pertinez HE, Chirambo AP, et al. High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2022. PMID: 35325074. doi:10.1093/cid/ciac228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。